30 June 2017 - Swedish Orphan Biovitrum today announces that for the first time people in England with the disabling hand condition Dupuytren’s disease will have access to Xiapex (collagenase clostridium histolyticum injections, a pharmacological treatment for contracture of their fingers, on the National Health Service after recommendation from NICE).

“The availability of funding for Xiapex within NHS England is an important milestone for the Dupuytren’s community in the UK, as healthcare professionals can now offer people with contracture a non-invasive treatment option,” says Neil Dugdale, General Manager UK & RoI at Sobi. “We are pleased that Sobi was able to work with NICE and ultimately achieve access for Dupuytren’s contracture patients in England. We are very grateful for the support of both the British Dupuytren’s Society and the British Society for Surgery of the Hand during this process.”

Read Sobi press release